Spyre Therapeutics financials
$84.72−1.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$81.6M | -$75.6M | -$57.2M | -$56.9M | -$51.9M | -$53.6M | -$61.3M | -$55.4M | -$44.1M | -$47.8M | -$47.8M |
| Net income | -$30.9M | -$58.2M | -$51.8M | -$9.0M | -$29.6M | -$36.1M | -$43.7M | -$53.7M | -$26.8M | -$26.4M | -$36.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.36 | $-0.74 | $-0.69 | $-0.15 | $-0.49 | $-0.60 | $-0.79 | $-1.06 | $-0.59 | $-0.72 | $-2.35 |
| EBITDA | -$81.6M | -$75.6M | -$57.2M | -$56.9M | -$51.9M | -$53.6M | -$61.3M | -$55.4M | -$44.1M | -$47.8M | $82.4M |
| Operating cash flow | -$69.9M | -$57.4M | -$44.6M | -$37.1M | -$46.6M | -$41.0M | -$37.2M | -$29.4M | -$62.2M | -$28.5M | -$31.0M |
| Free cash flow | -$69.9M | -$57.4M | -$44.6M | -$37.1M | -$46.6M | -$41.0M | -$37.2M | -$29.4M | -$62.2M | -$28.5M | -$31.0M |
| Diluted shares | 84.7M | 78.5M | 75.2M | 60.4M | 60.3M | 60.3M | 55.0M | 50.9M | 45.3M | 36.9M | 15.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $162.0M | $97.2M | $85.7M | $64.9M | $81.7M | $48.5M |
| Short-term investments | $983.3M | $644.3M | $670.8M | $421.3M | $444.9M | $516.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.17B | $764.0M | $777.8M | $504.6M | $538.8M | $569.8M |
| Total liabilities | $71.9M | $93.1M | $62.5M | $49.5M | $83.1M | $87.2M |
| Shareholders' equity | $1.10B | $670.8M | $715.2M | $455.1M | $455.8M | $482.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology